AbbVie's (ABBV) MAVIRET Approved by Health Canada for Treatment of Chronic Hepatitis C in All Major Genotypes
Tweet Send to a Friend
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that Health Canada has granted approval for MAVIRETâ„¢ (glecaprevir/pibrentasvir tablets), a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE